Evaxion Biotech A/S (NASDAQ:EVAX) Receives Buy Rating from HC Wainwright

Evaxion Biotech A/S (NASDAQ:EVAX)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research report issued on Friday, Benzinga reports. They currently have a $14.00 price target on the stock. HC Wainwright’s target price would suggest a potential upside of 440.54% from the stock’s current price.

Evaxion Biotech A/S Price Performance

Shares of NASDAQ EVAX opened at $2.59 on Friday. Evaxion Biotech A/S has a 1-year low of $2.26 and a 1-year high of $13.61. The business has a fifty day moving average price of $2.96 and a 200 day moving average price of $3.19. The company has a debt-to-equity ratio of 7.99, a quick ratio of 2.80 and a current ratio of 2.80.

Evaxion Biotech A/S (NASDAQ:EVAX) last issued its quarterly earnings data on Thursday, October 31st. The company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.08. The firm had revenue of $3.02 million during the quarter, compared to analysts’ expectations of $0.19 million. Research analysts anticipate that Evaxion Biotech A/S will post -0.24 earnings per share for the current fiscal year.

Institutional Trading of Evaxion Biotech A/S

A hedge fund recently bought a new stake in Evaxion Biotech A/S stock. Invst LLC bought a new stake in shares of Evaxion Biotech A/S (NASDAQ:EVAX) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 54,000 shares of the company’s stock, valued at approximately $156,000. Invst LLC owned approximately 1.00% of Evaxion Biotech A/S at the end of the most recent reporting period. Institutional investors and hedge funds own 11.04% of the company’s stock.

About Evaxion Biotech A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.